NCT00781443View on ClinicalTrials.gov

A Study to Evaluate MILR1444A in the Prevention of Allergen-Induced Airway Obstruction in Adults With Mild Allergic Asthma

PHASE2CompletedINTERVENTIONAL
Enrollment

29

Participants

Timeline

Start Date

December 31, 2008

Primary Completion Date

November 30, 2009

Conditions
Allergic Asthma
Interventions
DRUG

lebrikizumab (MILR1444A)

Repeating subcutaneous injection

DRUG

placebo

Repeating subcutaneous injection

Sponsors

Lead Sponsor

Genentech, Inc.
All Listed Sponsors
lead

Genentech, Inc.

INDUSTRY